Chronic lower back pain patients with a single injection have hope

Researchers have developed a single-injection treatment that could offer long-lasting relief for chronic lower back pain. The treatment, called SP-102, is a non-opioid medicine that is injected into the patient’s back. It contains a combination of two drugs — the steroid dexamethasone and the anesthetic bupivacaine.

A clinical trial involving more than 400 patients with moderate to severe chronic lower back pain found that a single injection of SP-102 provided significant pain relief for up to six months. The treatment was also found to be safe and well-tolerated by patients.

Chronic lower back pain affects millions of people worldwide and is often treated with opioids, which can lead to addiction and other serious side effects. SP-102 offers an alternative treatment option that does not carry the same risks.

The researchers hope that the new treatment will help to reduce the use of opioids for chronic pain management and improve the quality of life for patients with lower back pain.

The treatment has already been submitted to the US Food and Drug Administration (FDA) for approval. If approved, it could become available to patients as early as 2022.

In conclusion, a non-opioid, single-injection treatment called SP-102, which contains a combination of two drugs, has shown promising results in providing long-lasting relief for chronic lower back pain in a clinical trial involving over 400 patients. The treatment was found to be safe and well-tolerated by patients, and if approved by the FDA, it could become available as early as 2022, providing an alternative treatment option for patients with lower back pain that does not carry the risks associated with opioid use.

Regenerate response

ChatGPT Feb 13 Version. Free Research Preview. Our goal is to make AI systems more natural and safe to interact with. Your feedback will help us improve.